Pernix Therapeutics (PTX) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pernix Therapeutics (PTX) Target Price Lifted to $16 at Needham & Company
February 26, 2015 6:40 AM ESTNeedham & Company analyst Elliot Wilbur reiterated a Strong Buy and boosted his price target on Pernix Therapeutics (NASDAQ: PTX) to $16.00 (from $12.00)
Wilbur commented, "PTX closed out a transformational 2014 with solid 4Q14 financials that bolster our confidence in obtainment of 2015 guidance parameters. New Treximet... More
